SGHT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SGHT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Sight Sciences's revenue for the three months ended in Mar. 2024 was $19.27 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $81.50 Mil. Sight Sciences's Revenue per Share for the three months ended in Mar. 2024 was $0.39. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.67.
Warning Sign:
Sight Sciences Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Sight Sciences was 6.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was 28.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 44.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 6 years, Sight Sciences's highest 3-Year average Revenue per Share Growth Rate was 98.50% per year. The lowest was 27.20% per year. And the median was 28.30% per year.
The historical data trend for Sight Sciences's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Revenue | Get a 7-Day Free Trial | 23.35 | 27.64 | 48.96 | 71.33 | 81.06 |
Sight Sciences Quarterly Data | |||||||||||||||||||
Dec18 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Revenue | Get a 7-Day Free Trial | 18.82 | 23.47 | 20.01 | 18.75 | 19.27 |
For the Medical Devices subindustry, Sight Sciences's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Revenue distribution charts can be found below:
* The bar in red indicates where Sight Sciences's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $81.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences (NAS:SGHT) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Sight Sciences's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeremy B. Hayden | officer: Chief Legal Officer | 2 MUSICK, 2 MUSICK, IRVINE CA 92618 |
Sam Boong Park | officer: Chief Operating Officer | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025 |
Paul Badawi | director, 10 percent owner, officer: President and CEO | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025 |
David Badawi | director, officer: Chief Technology Officer | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025 |
D1 Capital Partners L.p. | 10 percent owner | 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019 |
Staffan Encrantz | director | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025 |
Matthew Link | officer: Chief Commercial Officer | 7475 LUSK BLVD, SAN DIEGO CA 92121 |
Catherine Mazzacco | director | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Alison Bauerlein | officer: See remarks | 326 BOLLAY DRIVE, GOLETA CA 93117 |
James Rodberg | officer: See Remarks | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVE., SUITE 100, MENLO PARK CA 94025 |
Tamara Fountain | director | C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656 |
Brenda Jane Larsen-becker | director | C/O SIGHT SCIENCES, INC., 3000 SAND HILL ROAD, BUILDING 3, STE 105, MENLO PARK CA 94025 |
Jesse Selnick | officer: Chief Financial Officer | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025 |
Daniel S. Sundheim | 10 percent owner | C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019 |
Erica J. Rogers | director | C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089 |
From GuruFocus
By PRNewswire PRNewswire • 01-04-2023
By sperokesalga sperokesalga • 04-26-2023
By sperokesalga sperokesalga • 04-13-2023
By GlobeNewswire GlobeNewswire • 05-06-2023
By Marketwired • 06-21-2023
By Marketwired • 10-12-2023
By Marketwired • 10-19-2023
By Marketwired • 09-11-2023
By Marketwired • 07-20-2023
By sperokesalga sperokesalga • 03-30-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.